Citigroup ups price target on Watson Pharmaceuticals

Watson Pharmaceuticals Inc. was reiterated at a hold with its price target increased to $37 from $35 by Citigroup Investment Research analyst Andrew Swanson. Citigroup said Watson's agreement with Purdue Pharma to become the generic manufacturer for Oxycontin will increase revenues. Shares of the Corona, Calif.-based biopharmaceutical company were up $0.33, or 0.94%, at $35.55 on volume of 1,132,100 shares versus the three-month running average of 993,488 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.